Document Detail


Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases.
MedLine Citation:
PMID:  12468962     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To study the frequency and specificity of acquired coagulation inhibitors in inflammatory and malignant gastrointestinal diseases. METHODS: In a 10-year period, 511 patients from the island of Crete in Greece were studied, 302 with ulcerative colitis, 112 with Crohn's disease, 82 with gastrointestinal carcinoma and 15 with gastrointestinal lymphoma. Prothrombin time and activated partial thromboplastin time were measured by routine methods. When prothrombin time and/or activated partial thromboplastin time were found to be prolonged, mixture experiments with 25%, 50% and 75% pooled normal human plasma were performed. If clotting times were inadequately corrected, the presence of an acquired inhibitor against a coagulation factor was suggested. Specific coagulation factor assays were then performed with deficient plasmas. RESULTS: Fifteen patients acquired inhibitors to the following coagulation factors within the 10-year observation period: factor IX (four patients); factor X (three patients); factor XII (three patients); factor VIII (two patients); factor XI (two patients); and factor V (one patient). The activity of the above factors varied from < 1% to 10%. Five patients with ulcerative colitis, six with Crohn's disease, two with gastrointestinal lymphoma and two with gastrointestinal carcinoma developed an inhibitor. Only one patient with factor VIII inhibitor presented with severe bleeding and was treated with recombinant human activated factor VII, while the others had no complications. Remission was obtained in all patients after immunosuppressive therapy, chemotherapy or tumour resection. CONCLUSION: An increased incidence of coagulation factor inhibitors was found in patients with gastrointestinal inflammatory and malignant diseases compared to the healthy population. In addition, an increased incidence of these inhibitors was also found in the common population of Crete compared to that found in other areas.
Authors:
Despina S Kyriakou; Michael G Alexandrakis; Freda H Passam; Kalliopi Foundouli; Emmanouel Matalliotakis; Ioannis E Koutroubakis; Taxiarchis V Kourelis; George Chalkiadakis; Orestis N Manoussos
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  14     ISSN:  0954-691X     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-06     Completed Date:  2003-03-17     Revised Date:  2009-10-16    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1383-7     Citation Subset:  IM    
Affiliation:
Department of Haematology, University Hospital of Heraklion, Crete, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Blood Coagulation Factors / antagonists & inhibitors*
Colitis, Ulcerative / blood*
Crohn Disease / blood*
Female
Gastrointestinal Neoplasms / blood*
Hemorrhagic Disorders / blood,  etiology
Humans
Lymphoma / blood*
Male
Middle Aged
Partial Thromboplastin Time
Prothrombin Time
Chemical
Reg. No./Substance:
0/Blood Coagulation Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection.
Next Document:  Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resultin...